share_log

Panbela Therapeutics | 10-K: FY2023 Annual Report

Panbela Therapeutics | 10-K: FY2023 Annual Report

Panbela Therapeutics | 10-K：2023财年年报
美股sec公告 ·  03/26 16:20
Moomoo AI 已提取核心信息
Panbela Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $25.3 million for the fiscal year ended December 31, 2023, compared to a net loss of $34.9 million for the previous year. The company's operating expenses decreased by 24.8% to $25.6 million, down from $34.1 million in 2022, primarily due to reduced legal and financial advisory expenses and a decrease in research and development costs. Despite the net loss, Panbela made progress in its clinical trials, including the initiation of the ASPIRE trial for its lead candidate ivospemin (SBP-101) for the treatment of pancreatic cancer. The company also completed a strategic acquisition of Cancer Prevention Pharmaceuticals (CPP) and raised significant capital through public offerings and warrant exercises, totaling approximately $26.1 million in net financing activities. Panbela's cash and cash equivalents stood at $2.6 million as of December 31, 2023. The company's future plans include continuing its clinical development efforts, seeking regulatory approvals, and exploring additional financing options to support operations beyond the second quarter of 2024.
Panbela Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $25.3 million for the fiscal year ended December 31, 2023, compared to a net loss of $34.9 million for the previous year. The company's operating expenses decreased by 24.8% to $25.6 million, down from $34.1 million in 2022, primarily due to reduced legal and financial advisory expenses and a decrease in research and development costs. Despite the net loss, Panbela made progress in its clinical trials, including the initiation of the ASPIRE trial for its lead candidate ivospemin (SBP-101) for the treatment of pancreatic cancer. The company also completed a strategic acquisition of Cancer Prevention Pharmaceuticals (CPP) and raised significant capital through public offerings and warrant exercises, totaling approximately $26.1 million in net financing activities. Panbela's cash and cash equivalents stood at $2.6 million as of December 31, 2023. The company's future plans include continuing its clinical development efforts, seeking regulatory approvals, and exploring additional financing options to support operations beyond the second quarter of 2024.
临床阶段生物制药公司Panbela Therapeutics报告了2023年12月31日结束的财政年度的净亏损为2530万美元，而上一年的净亏损为3490万美元。公司的营业费用减少了24.8％，从2022年的3410万美元降至2560万美元，主要是由于减少了法律和财务咨询费用以及研发成本的下降。尽管出现了净亏损，Panbela在其临床试验方面取得了进展，包括启动了ASPIRE试验，以研究其治疗胰腺癌的主要候选药物ivospemin(SBP-101)。该公司还通过公开发行和权证行使筹集了大量资本，净融资活动总额约为2610万美元。截至2023年12月31日，Panbela的现金及现金等价物为260万美元。该公司未来的计划包括继续开展临床发展工作，寻求监管批准，并探索其他融资选择，以支持2024年第二季度之后的运营。
临床阶段生物制药公司Panbela Therapeutics报告了2023年12月31日结束的财政年度的净亏损为2530万美元，而上一年的净亏损为3490万美元。公司的营业费用减少了24.8％，从2022年的3410万美元降至2560万美元，主要是由于减少了法律和财务咨询费用以及研发成本的下降。尽管出现了净亏损，Panbela在其临床试验方面取得了进展，包括启动了ASPIRE试验，以研究其治疗胰腺癌的主要候选药物ivospemin(SBP-101)。该公司还通过公开发行和权证行使筹集了大量资本，净融资活动总额约为2610万美元。截至2023年12月31日，Panbela的现金及现金等价物为260万美元。该公司未来的计划包括继续开展临床发展工作，寻求监管批准，并探索其他融资选择，以支持2024年第二季度之后的运营。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

独立文件9  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息